Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Selicrelumab |
| Trade Name | |
| Synonyms | RO7009789|CP 870,893 |
| Drug Descriptions |
Selicrelumab (RO7009789) is a monoclonal antibody to TNFRSF5 (CD40), which mimics the binding of the ligand, CD40LG (CD40L), to stimulate proliferation of T-cells and enhance an anti-tumor response (PMID: 26386124). |
| DrugClasses | CD40 Antibody 16 |
| CAS Registry Number | 1622140-49-1 |
| NCIT ID | C119740 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + Bevacizumab + Selicrelumab | Atezolizumab Bevacizumab Selicrelumab | 0 | 0 |
| Atezolizumab + Gemcitabine + Nab-paclitaxel + Selicrelumab | Atezolizumab Gemcitabine Nab-paclitaxel Selicrelumab | 0 | 0 |
| Bevacizumab + Selicrelumab | Bevacizumab Selicrelumab | 0 | 1 |
| Emactuzumab + Selicrelumab | Emactuzumab Selicrelumab | 0 | 1 |
| RO5520985 + Selicrelumab | RO5520985 Selicrelumab | 0 | 1 |
| Selicrelumab | Selicrelumab | 0 | 1 |